[Metabolic, hormonal and nutritional effects of long-term theophylline therapy in preterm infants: a case-control study].
Theophylline is widely used in preterm newborns for the prevention of idiopathic apnoeas, but few controlled studies have evaluated its effects on the nutritional and hormonal status of the infant. For this reason we have studied the effect of long term theophylline administration on 16 laboratory parameters concerning the metabolism of proteins, glucose, lipids, hormones and the glomerular function (blood: hemoglobin, glucose, albumin, prealbumin, urea nitrogen, creatinine, cholesterol, triglycerides, apolipoproteins A-I and B-100, IGF-I, IGFBP-3; urine: urea nitrogen, creatinine, C-peptide, GH). A case-control study was performed on 18 healthy preterm infants who were receiving oral theophylline for the prevention of idiopathic apnoeas. The mean duration of therapy at the moment of the balance study was 31 days (SD 12, range 12-51), the mean daily dose was 4.2 mg/kg (SD 1.0), the plasma range of theophylline concentration was 5 to 15 mg/l. As controls, 18 healthy preterm infants of comparable post-conceptional age, body weight and calories/protein intake at the moment of the study, were selected if they had been never treated with theophylline. No statistically significant differences were found between the two groups for the growth velocity or any of the parameters studied. The only notable exception was hemoglobin, which was significantly lower in theophylline treated infants (mean values 10.5 vs 12.7 g/dl, p 0.005 at t test). In synthesis, long term theophylline treatment in preterm infants seems to be safe from the point of view of growth, glucose, protein and lipid metabolism, hormones and glomerular function, but further studies are needed on the effects of theophylline on neonatal erythropoiesis.
D000367:Age Factors; D001049:Apnea / Q000097:blood / Q000378:metabolism / Q000517:prevention & control*; D001786:Blood Glucose / Q000032:analysis; D001798:Blood Proteins / Q000378:metabolism; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology*; D002096:C-Peptide / Q000097:blood; D005919:Glomerular Filtration Rate; D006128:Growth / Q000187:drug effects; D013006:Growth Hormone / Q000652:urine; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000097:blood / Q000378:metabolism / Q000517:prevention & control*; D008055:Lipids / Q000097:blood; D013806:Theophylline / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology*; D013997:Time Factors
D001786:Blood Glucose; D001798:Blood Proteins; D001993:Bronchodilator Agents; D002096:C-Peptide; D008055:Lipids; D013006:Growth Hormone; D013806:Theophylline
Effetti metabolici, ormonali e nutrizionali della terapia prolungata con teofillina nei nati pretermine: uno studio caso-controllo.